EGFR is frequently overexpressed on several cancers, and two targeted antibodies are FDA
approved but differ by isotype. Cetuximab (IgG1 isotype) has been shown to be effective at …

Purpose: EGF receptor (EGFR) is highly overexpressed on several cancers and two targeted
anti-EGFR antibodies which differ by isotype are FDA-approved for clinical use. Cetuximab …

The tumor antigen (TA)-targeted monoclonal antibodies (mAb) cetuximab and panitumumab
target the human epidermal growth factor receptor and have been integrated into treatment …

Objective To determine if the epidermal growth factor receptor (EGFR)-specific monoclonal
antibodies (mAbs) cetuximab or panitumumab mediate in vitro immune activation against …

6060 Background: Despite near universal EGFR expression in HNSCC, the anti-EGFR
antibody, cetuximab, improves survival in only 15% of patients. Activation of immune cell …

e13025 Background: Therapeutic antibodies can affect tumor cells by functionally interfering
with the target and/or by employing immune effector mechanisms such as antibody …

Importance of the field: EGFR is an established therapeutic target in head and neck
squamous cell carcinoma (HNSCC). The EGFR-targeting monoclonal antibody cetuximab …

11055 Targeted therapy against the epidermal growth factor receptor (EGF-R) has been
introduced into clinical practice for several solid tumors. Thus far, EGF-R-directed antibodies …

Abstract Purpose of Review The efficacy of anti-EGFR therapy is still unfavorable in
recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) patients …

Three FDA-approved epidermal growth factor receptor (EGFR) antibodies (cetuximab,
panitumumab, necitumumab) are clinically available to treat patients with different types of …